Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSWhile individual rare diseases might impact a small fraction of the global population, they are collectively a public health priority. With increased awareness about and diagnosis of rare diseases, over 7000 have been identified, yielding a prevalence rate of 3.5%–5.9% and affecting around 260–440 million individuals worldwide, with the majority being children [1][2]. Some diseases which are initially classified into rare disease might outgrow this classification – one significant example being Restless legs syndrome (RLS), which was considered as a rare disease until 2010 [3].
Regardless of the size of the population affected, investments in developing therapies for rare diseases have increased over the past few years, both in terms of new drug candidates and dollar value. Fueled by favorable government policies including accelerated clinical development, incentives for pediatric drug development, extended exclusivity, and lower commercialization costs, there is an increased focus on rare diseases among pharmaceutical companies.
There is also a huge unmet medical need with approximately 95% of rare diseases having no FDA approved treatment. In addition to large pharma, smaller biotechnology companies are often involved in initial development of a drug molecule which may later be marketed/acquired by larger pharmaceutical companies. With the rise in the number of pharmaceutical players involved in the development of rare therapies and the rise in cell and gene therapy assets/technology, the market for rare disease treatments is rapidly growing and becoming even more competitive, creating information gaps for the pharmaceutical company in their clinical and commercial decision making. Examples of prominent pharma players with strong rare disease pipelines include Novartis, Roche, Celgene, BMS, Shire, Merck, J&J, Pfizer, Biogen, Sanofi, AstraZeneca, and Takeda.
In the last few years, there has been an increase in the number of orphan drug approvals by the FDA. In 2022, the FDA approved 20 orphan drugs out of the Center for Drug Evaluation and Research (CDER) 37 novel drugs (54%), of which 9 orphan drugs were granted fast track approval (45%). In terms of therapeutic classification, 9 out of 20 are oncology molecules (45%) [4]. Similarly, in 2021, the FDA approved 26 orphan drugs out of CDER’s 50 novel drugs (52%) [5]. Other notable trends in the rare disease space [Image 1] are:
IQVIA has long-standing expertise in the rare disease space, offering strategic and clinical research solutions to our customers. IQVIA’s Cell and Gene Therapy Center of Excellence (CoE), Pediatric and Rare Disease CoE, and Primary Intelligence team collaboratively possess vast clinical and market research experience across multiple therapeutic areas in rare diseases, including but not limited to metabolic, neurology, hematology, and cardiology. Combining the inputs from our medical experts and primary market research experts, IQVIA is differentiated by the combination of our therapeutic area-based CoEs and dedicated Rare Disease and Cell and Gene Therapy (CAGT) CoEs.
We also incorporate input from and partner with healthcare professionals, patients/caregivers, and patient advocacy groups to bring a holistic view of the market and provide direct insights to our customers to support their clinical and commercial strategies. We provide end-to-end support in designing rare disease programs, ranging from pre-clinical support like regulatory strategy through commercial support and market access strategy. Together, we are helping our customers understand important business aspects of the rare disease market and develop strategic recommendations, at both the therapeutic area and indication level.
IQVIA has multiple touchpoints in primary market research, including physicians, patients/caregivers, payers and patient advocacy groups, conveying challenges and perspectives that help generate strategic insights. IQVIA has dedicated teams that work with customers on their requirements, identifying unmet needs and opportunities for customers by establishing the rare disease patient journey, market dynamics, demands and access to therapies. These assessments empower customers to formulate their strategy, thus making sound investment decisions. With rare diseases, it is particularly important to strategize due to many grey areas still prevailing and gaps still needing to be filled.
IQVIA is committed to contributing to the advancement of the rare disease clinical trial landscape to facilitate better diagnosis and treatment for patients who, too often, live with limited therapeutic options. As highlighted in this blog, IQVIA provides unparalleled market research alongside our scientific expertise to provide any rare disease stakeholder with customized, fit-for-purpose solutions. Please contact us to learn more about how we can help you advance and manage the rare disease product and brand lifecycles.
[1] Epidemiology of rare diseases is important. Journal of the European Academy of Dermatology and Venereology. Accessed June 2023. Available from: https://onlinelibrary.wiley.com/doi/10.1111/jdv.17165
[2] National Organization for Rare Disorders. Accessed June 2023. Available from: https://rarediseases.org/
[3] Algorithms for the diagnosis and treatment of restless les syndrome in primary care. Accessed June 2023. Available from: https://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-11-28
[4] New Drug Therapy Approvals 2022. Accessed June 2023. Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2022
[5] New Drug Therapy Approvals 2021. Accessed June 2023. Available from: https://www.fda.gov
[6] European Medicines Agency: Market Exclusivity: Orphan drugs
[7] IQVIA Institute for Human Data Science. Orphan Drugs in the United States: Exclusivity, Pricing and Treated Populations. 2018 Dec. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/orphan-drugs-in-the-united-states-exclusivity-pricing-and-treated-populations.pdf
[8] Using four decades of FDA orphan drug designations to describe trends in rare disease drug development. Accessed June 2023. Available from: https://ojrd.biomedcentral.com/articles/10.1186/s13023-021-01901-6
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.
Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.
Be proactive about growing your brand using the latest in data, analytics, and domain expertise.
Discover actionable brand insights at the intersection of market research and advanced analytics.
